The estimated Net Worth of Howard G. Welgus is at least $2.71 Million dollars as of 3 September 2024. Howard Welgus owns over 10,000 units of Arcutis Biotherapeutics Inc stock worth over $2,019,251 and over the last 5 years he sold ARQT stock worth over $691,434. In addition, he makes $0 as Director at Arcutis Biotherapeutics Inc.
Howard has made over 46 trades of the Arcutis Biotherapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of ARQT stock worth $107,700 on 3 September 2024.
The largest trade he's ever made was exercising 19,861 units of Arcutis Biotherapeutics Inc stock on 4 February 2021 worth over $33,366. On average, Howard trades about 3,995 units every 31 days since 2020. As of 3 September 2024 he still owns at least 191,944 units of Arcutis Biotherapeutics Inc stock.
You can see the complete history of Howard Welgus stock trades at the bottom of the page.
Dr. Howard G. Welgus M.D. has been appointed as Director of the Company effective 8/1/2020. From February 2016 to June 2018, Dr. Welgus served as the Chief Medical Officer at Verrica Pharmaceuticals Inc. Prior to joining Verrica, Dr. Welgus served as the Chief Medical Officer at Thesan Pharmaceuticals Inc. from September 2012 to November 2016 and served as the Chief Medical Officer at Nycomed US Inc. from May 2009 to November 2010. From 1999 to 2009, he served as the Vice President and head of the Dermatology and Inflammation therapeutic areas in Discovery at Pfizer Inc. in Ann Arbor, MI. Prior to joining the private sector, Dr. Welgus was a faculty member at Washington University for 17 years. Dr. Welgus is a board-certified dermatologist and received a M.D. from Washington University School of Medicine in St. Louis and a B.A. in Biology from Rice University.
Howard Welgus is 68, he's been the Director of Arcutis Biotherapeutics Inc since 2020. There are no older and 27 younger executives at Arcutis Biotherapeutics Inc.
Howard's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361.
Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron und Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.
arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.
Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include: